Seelos therapeutics to present a poster on sls-005 in alzheimer's disease at neuroscience 2023

-sls-005 induces autophagy to reduce mutant protein aggregates, and is currently being studied in alzheimer's disease, huntington's disease, amyotrophic lateral sclerosis and spinocerebellar ataxia new york , oct. 27, 2023 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel) ("seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has been selected to present a poster from a study of sls-005 (trehalose injection, 90.5 mg/ml for intravenous infusion) in a tauopathy model of alzheimer's disease at the society for neuroscience's neuroscience 2023 meeting, to be held on november 11-15, 2023, at the walter e. washington convention center in washington, d.c.
SEEL Ratings Summary
SEEL Quant Ranking